Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 ROE % is 2.05% as of Sep. 2025, which is 87% below its 10-year median of 15.87. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 936 Drug Manufacturers companies, Sai Parenteral's ranks worse than 65.71% on this metric.
Sai Parenteral's (NSE:SAIPARENT) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Sai Parenteral's ROE % Related Terms
Sai Parenteral's ROE % Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's ROE % Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
ROE %
13.90
15.87
21.10
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
ROE %
0.00
0.00
0.00
2.05
NSE:SAIPARENT vs LLY, JNJ, ABBV: ROE % Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's ROE % distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Sai Parenteral's (NSE:SAIPARENT) has a ROE % of 2.05% as of Sep. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sai Parenteral's and its competitors. This is 87% below median its historical median of 15.87. Over the past decade, Sai Parenteral's' ROE % has ranged from 1.02 to 21.10. According to the industry distribution chart, Sai Parenteral's ranks #615 out of 936 companies in the Drug Manufacturers industry, placing it in the top 65.7%.
Is Sai Parenteral's' ROE % too high?
Sai Parenteral's' current ROE % of 2.05% is 87% below median its 10-year median of 15.87. Over the past 10 years, this metric has ranged from a low of 1.02 to a high of 21.10. The Drug Manufacturers industry median ROE % is 5.88. Sai Parenteral's' value of 2.05% is 65.1% below this industry median. Based on the distribution chart, Sai Parenteral's ranks #615 out of 936 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' ROE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #615 out of 936 companies for ROE %. This places Sai Parenteral's in the lower half of its industry. The industry median ROE % is 5.88. Sai Parenteral's' value of 2.05% is 65.1% below this benchmark. Historically, Sai Parenteral's' own ROE % has ranged from 1.02 to 21.10 over the past decade. While the company's 10-year median is 15.87 vs. the industry median of 5.88, Sai Parenteral's has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.88, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current ROE % of 2.05% is 65.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current ROE % is 2.05%, which is 87% below median its own 10-year median of 15.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current ROE % of 2.05%. The current ROE % is 2.05%, which is 87% below median its 10-year median of 15.87 and 65.1% below the Drug Manufacturers industry median of 5.88. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current ROE % is 2.05% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
